Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes

March 15, 2024 updated by: Ong Ying Qian, Universiti Sultan Zainal Abidin

Acute Effect of Melon Manis Terengganu Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes

Open-label, randomised, placebo-controlled, crossover study with two intervention arms. The study was conducted in 30 respondents and the primary objective is to show an improved glycemic response after Melon Manis Terengganu (MMT) peel powder consumption in people at risk of type 2 diabetes.

Study Overview

Status

Completed

Detailed Description

The main aim of the study is to investigate the acute effect of MMT peel powder on glycemic response in people at risk of type 2 diabetes. Besides, the acute effect of MMT peel powder on perceived satiety and energy intake were explored.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Terengganu
      • Kuala Terengganu, Terengganu, Malaysia, 21300
        • Food Preparation and Therapeutic Diet Lab, Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Gong Badak Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 59 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Modified Finnish Type 2 Diabetes Risk Assessment Tool (FINDRISC) score ≥ 4
  • Capillary fasting blood glucose (FBG) < 7.0 mmol/L
  • Malaysian
  • Live, work or study in Kuala Nerus, Terengganu
  • Both gender
  • Age 18 to 59 years old
  • Non-smoker
  • Those taking supplement agree to undergo washout period of one week

Exclusion Criteria:

  • Had clinical history of type 2 diabetes mellitus (T2DM)
  • Capillary FBG ≥ 7.0 mmol/L
  • Take oral antidiabetic agents
  • Participate in other weight management programme or interventional research
  • On a prescribed medical diet
  • GI illnesses or conditions
  • Allergy or sensitivity to study products
  • Pregnant, currently breastfeeding, or planning to become pregnant
  • On dietary restrictions
  • Smoker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Formulation 3
Formulated MMT peel powder (provide 5 g dietary fiber per day)
Respondents were consumed 36 g of Formulation 3 containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
Other Names:
  • Formulated MMT peel powder
Placebo Comparator: Control
Glucose
Respondents were consumed 4.5 g of control containing 4.5 g of available carbohydrate dissolved in 180 ml water with study breakfast
Other Names:
  • Glucose

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Glucose Levels
Time Frame: Baseline (0 min), 30, 60, 90 and 120 minutes on Day 1 and Day 4 of both study visits
Blood glucose were measured using glucometer (Accu Chek Performa, New South Wales, Australia) from finger-prick blood samples according to the standard operating procedure at baseline (0 min), 30, 60, 90 and 120 minutes.
Baseline (0 min), 30, 60, 90 and 120 minutes on Day 1 and Day 4 of both study visits

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived Satiety (Area Under the Curve)
Time Frame: Day 1 and 4 of both study visits
Perceived satiety measurements were rated using a 10-cm visual analogue scale (VAS) which consisted of hunger (How hungry are you?), fullness (How full are you?), desire to eat (How strong is your desire to eat?), prospective food consumption (How much would you be able to eat right now?) and thirstiness (How thirsty are you?) (Tey, Salleh, Henry, & Forde, 2017). The scale ranged from 0 (not at all) to 10 (very much) measured at baseline (0 min), 30, 60, 90 and 120 minutes. The area under the curve was calculated using trapezoid rule.
Day 1 and 4 of both study visits
Food Intake
Time Frame: Day 1 and 4 of both study visits
The respondents were asked to record all the food or drink they had consumed including sauces, soup and gravies using household measures once they woke up in the morning until they went to sleep at night.
Day 1 and 4 of both study visits
Calories Intake
Time Frame: Day 1 and day 4 of both study visits
The respondents were asked to record all the food or drink they had consumed including sauces, soup and gravies using household measures once they woke up in the morning until they went to sleep at night.
Day 1 and day 4 of both study visits

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Weight (kg)
Time Frame: Day 1 and 4 of both study visits
Body weight was taken at every study visit.
Day 1 and 4 of both study visits
Height (cm)
Time Frame: Day 1 and 4 of both study visits
Height was taken at every study visit.
Day 1 and 4 of both study visits
Body Mass Index (BMI) (kg/m^2)
Time Frame: Day 1 and 4 of both study visits
BMI was calculated using formula = body weight (kg)/height (m)^2
Day 1 and 4 of both study visits
% Body Fat
Time Frame: Day 1 and 4 of both study visits
% body fat was taken at every study visit.
Day 1 and 4 of both study visits
Waist Circumference (cm)
Time Frame: Day 1 and 4 of both study visits
Waist circumference was taken at every study visit.
Day 1 and 4 of both study visits
Blood Pressure
Time Frame: Day 1 and 4 of both study visits
Blood pressure was measured using an Omron automatic digital blood pressure monitor (Omron HEM-7221) in a seated position at all visits after 5 min of sitting.
Day 1 and 4 of both study visits

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Prof Dr Sakinah Harith, Universiti Sultan Zainal Abidin
  • Principal Investigator: Dr Norshazila Shahidan, Universiti Sultan Zainal Abidin
  • Principal Investigator: Prof Madya Dr Mohd Razif Shahril, National University of Malaysia
  • Principal Investigator: Prof Madya Dr Hermizi Hapidin, Universiti Sains Malaysia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2021

Primary Completion (Actual)

November 3, 2021

Study Completion (Actual)

November 3, 2021

Study Registration Dates

First Submitted

March 1, 2022

First Submitted That Met QC Criteria

March 16, 2022

First Posted (Actual)

March 28, 2022

Study Record Updates

Last Update Posted (Actual)

August 15, 2024

Last Update Submitted That Met QC Criteria

March 15, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on At Risk of Type 2 Diabetes Mellitus

Clinical Trials on Formulation 3

Subscribe